Case Study: Rhythm Pharmaceuticals accelerates rare obesity trial design with Genomenon

Rhythm Pharmaceuticals maps 10,000+ obesity variants in weeks with Genomenon

Rhythm Pharmaceuticals, a company advancing therapies for rare genetic disorders of obesity, faced a significant challenge in designing clinical trials for its lead program. Their internal team had spent years manually curating genetic variants from scientific literature, a slow and incomplete process that risked missing patients and overlooking potential label expansion opportunities due to inconsistent nomenclature and gaps in public databases. To overcome this, they turned to Genomenon and its Mastermind genomic database software.

Genomenon delivered a comprehensive, AI-powered solution that extracted, normalized, and classified over 10,000 mutations. This provided Rhythm with a complete, trial-ready dataset that de-risked and accelerated their trial design by ensuring no eligible patient group was overlooked. The results included improved recruitment accuracy and a robust evidence base that supported both their initial regulatory filing and a data-driven strategy for future label expansion into related rare obesity indications.

Rhythm Pharmaceuticals